Eris Lifesciences
Market cap ₹18,551 Cr
- P/E
- 26.00
- Day range
- ₹1,315.20 – ₹1,381.10
- 52-week range
- ₹1,069.00 – ₹1,740.00
- Volume
- 2.05 L
- Open
- ₹1,361.00
- Prev close
- ₹1,361.30
Latest results · Q2 FY27(consolidated)Revenue ₹892 Cr+12.6%Profit ₹187 Cr+39.2%Margin 21.0%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter pledge went up
21.25% of promoter shares pledged, up from 16.85% · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
ERIS in NSE indices and F&O
Research profile
Composite 56 / 100Factor percentiles
Derived metrics
- Earn. yield
- 3.8%
- Graham no.
- ₹608.42
- vs Graham
- -54.5%
- ROE ÷ P/B
- 4.4%
- 12-1 mom.
- -28.1%
- Return / vol
- -0.54
- Magic Formula
- #310
- Piotroski
- 4/6
- FCF yield
- 1.3%
- PEG
- 0.66
Appears in 11 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Eris LifesciencesERIS | ₹18,551 Cr | 26.00 | 4.37 | 19.2% | 14.0% | 35.0% | 0.59 | +12.6% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 9h agoHeadlines about Eris Lifesciences from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 24.8
- Price / Book
- 4.47
- ROE (FY26)
- 19.2%
- ROCE (latest year)
- 14%
- Dividend yield
- 0.54%
Moving averages (NSE)
- 20-day
- ₹1,215.94
- Price above
- 50-day
- ₹1,230.08
- Price above
- 200-day
- ₹1,340.12
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 486 | 551 | 720 | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 | 892 |
| Expenses | 311 | 402 | 470 | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 | 584 |
| Operating Profit | 176 | 148 | 250 | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 | 308 |
| OPM % | 36% | 27% | 35% | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% | 35% |
| Other Income | 4 | 15 | 2 | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 | -33 |
| Interest | 18 | 33 | 60 | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 | 46 |
| Depreciation | 46 | 54 | 76 | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 | 73 |
| Profit before tax | 116 | 77 | 116 | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 | 156 |
| Tax % | 12% | -4% | 22% | 25% | 25% | 21% | 22% | 22% | 25% | -75% | 20% | -20% |
| Net Profit | 101 | 80 | 90 | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 | 187 |
| EPS in Rs | ₹7.55 | ₹5.22 | ₹6.12 | ₹6.73 | ₹6.15 | ₹6.89 | ₹8.66 | ₹8.82 | ₹7.32 | ₹20.33 | ₹10.28 | ₹13.25 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+37 days since Mar 2021
+55 days since Mar 2021
-6 days since Mar 2021
+99 days since Mar 2021
-135 days since Mar 2021
Strengths, risks & growth
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products. [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 4.48 times its book value
- Tax rate seems low
- Company might be capitalizing the interest cost
Compounded Sales Growth
- 10 Years
- +18%
- 5 Years
- +21%
- 3 Years
- +23%
- TTM
- +11%
Compounded Profit Growth
- 10 Years
- +17%
- 5 Years
- +12%
- 3 Years
- +19%
- TTM
- +80%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- +12%
- 3 Years
- +13%
- 1 Year
- -17%
Return on Equity
- 10 Years
- +21%
- 5 Years
- +18%
- 3 Years
- +16%
- Last Year
- +19%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 54.85% | 53.92% | 54.14% | 54.74% | +0.60 pp |
| FII | 6.85% | 6.39% | 5.76% | 5.74% | -0.02 pp |
| DII | 20.31% | 20.35% | 20.71% | 20.19% | -0.52 pp |
| Public | 17.97% | 19.33% | 19.39% | 19.32% | -0.07 pp |
Filed with NSE for Sept 2026: promoters 54.74%, public 45.26%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 17.98% (-0.90 pp)- Promoters54.7%
- Foreign institutions5.7%
- Mutual funds18.0%
- Insurance1.5%
- Other domestic institutions0.7%
- Retail2.5%
- Others16.8%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Small Cap Fund | 4.05% | 1.92% | -0.18 pp |
| Franklin India Small Cap Fund | 1.50% | 2.08% | -0.01 pp |
| HDFC Aggressive Hybrid Fund | 1.44% | 1.27% | -0.21 pp |
| Franklin India Flexi Cap Fund | 0.95% | 0.96% | -0.01 pp |
| DSP Small Cap Fund | 0.77% | 0.70% | -0.12 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 29.8%
- Downside volatility
- 27.5%
- Worst 5% of days
- 3.1%
- Average of that tail
- 4.0%
- Max drawdown (1Y)
- 35.6%
- Below its peak
- 21.4%
Against the market
- Beta vs Nifty 50
- 0.58
- Correlation
- 0.26
- Relative strength (3M)
- -4.7%
- ATR (14)
- 3.3%
Return
- Return 1M
- +16.8%
- Return 3M
- -0.9%
- Return 6M
- -0.3%
- Return 1Y
- -16.0%
- vs 200-day average
- -0.2%
Momentum
- RSI (14)
- 69.6
- MACD histogram
- 20.64
- Stochastic %K
- 81.1
- ADX (14)
- 36.9
- +DI / −DI
- 29.9 / 8.1
- Money flow index
- 96.2
Participation
- Delivery (20d avg)
- 52.1%
- vs its 60-day baseline
- -1.9 pts
- Volume vs 20-day
- +0.4σ
- Close vs day's VWAP
- -1.5%
- 52-week position
- 40 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- ₹241 Cr
- FCF yield
- 1.3%
- Cash conversion
- 0.83
- Accruals ratio
- 0.015
- Net debt
- ₹2,191 Cr
- Net debt / equity
- 0.53
- EV / sales
- 6.23
- PEG
- 0.66
- Capex intensity
- 9.5%
- Revenue CAGR
- 17.0%
- Profit CAGR
- 49.5%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹7.21
Interim Dividend - Rs 7.21 Per Share
29 May 2026ex-date - dividend₹7.35
Interim Dividend - Rs 7.35 Per Share
13 Feb 2025ex-date - otherNot available — not reported in this filing
Annual General Meeting
17 Sept 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
15 Sept 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Aug 2022ex-date - dividend₹7.35
Interim Dividend- Rs 7.35 Per Share
11 Aug 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Aug 2021ex-date - dividend₹6.01
Interim Dividend - Rs 6.01 Per Share
5 Aug 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
18 Sept 2020ex-date - dividend₹5.50
Interim Dividend - Rs 5.50 Per Share
13 Aug 2020ex-date - dividend₹2.87
Interim Dividend - Rs 2.87 Per Share
19 Mar 2020ex-date - otherNot available — not reported in this filing
Annual General Meeting
18 Sept 2019ex-date - buybackNot available — not reported in this filing
Buyback
12 Jul 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
19 Sept 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
20 Sept 2017ex-date
Company announcements
as attached
as attached
as attached
The Company will host "Eris Investor Meet - 2026" on November 19, 2026
as attached
as attached
as attached
as attached
as attached
As Attached
As Attached
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve Financial Results
As Attached
As Attached
As Attached
Filed with BSE (scrip 540596); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Buyback - POST BUYBACK PUBLIC ADVERTISEMENT
ERIS LIFESCIENCES LIMITED - POST BUYBACK PUBLIC ADVERTISEMENT
27 Jan 2020Read on SEBI - Buyback
Eris Lifesciences Limited
26 Dec 2019Read on SEBI - Buyback - Draft Letter of Offer
Eris Lifesciences Ltd. - Draft Letter of Offer
16 Jul 2019Read on SEBI - Buyback - Public Announcement
Eris Lifesciences Ltd. - Public Announcement
9 Jul 2019Read on SEBI
Documents
Annual reports
Earnings calls
- Oct 2026SlidesRecording
- Jul 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlides
- Nov 2025TranscriptSlides
- Aug 2025TranscriptSlides
Credit ratings
- Rating update · 8 May from fitch
- Rating update · 9 May 2025 from fitch
- Rating update · 5 May 2025 from fitch
- Rating update · 28 May 2024 from fitch
- Rating update · 15 Mar 2024 from fitch
- Rating update · 11 Mar 2024 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 26 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Eris Lifesciences: common questions
Answered from the figures on this page.